KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EPS (Basic) (2016 - 2025)

Alnylam Pharmaceuticals' EPS (Basic) history spans 17 years, with the latest figure at $0.84 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 229.23% year-over-year to $0.84; the TTM value through Dec 2025 reached $2.1, up 196.77%, while the annual FY2025 figure was $2.39, 209.63% up from the prior year.
  • EPS (Basic) reached $0.84 in Q4 2025 per ALNY's latest filing, down from $1.91 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.91 in Q3 2025 to a low of -$3.32 in Q3 2022.
  • Average EPS (Basic) over 5 years is -$1.0, with a median of -$1.24 recorded in 2023.
  • The largest YoY upside for EPS (Basic) was 319.54% in 2025 against a maximum downside of 292.31% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$2.16 in 2021, then rose by 22.22% to -$1.68 in 2022, then surged by 35.12% to -$1.09 in 2023, then soared by 40.37% to -$0.65 in 2024, then surged by 229.23% to $0.84 in 2025.
  • Per Business Quant, the three most recent readings for ALNY's EPS (Basic) are $0.84 (Q4 2025), $1.91 (Q3 2025), and -$0.51 (Q2 2025).